No public English COA is assigned to this specification yet.
COA · ENGLISH · TSM2The public COA is shown in English and kept in its original laboratory form. Internal self-inspection COAs are private.
Muscle growth & growth hormone
Tesamorelin research material is available in 2mg, 5mg, 10mg, 20mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Tesamorelin research material is available in 2mg, 5mg, 10mg, 20mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
LYSENTA research catalogue
Description
Tesamorelin research material is available in 2mg, 5mg, 10mg, 20mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Supplied strictly as laboratory research material. Record the selected SKU, batch and COA in the research workflow.
Frequently asked questions
The displayed price is per vial. The spreadsheet box price has been divided by 10 without changing its total: selecting 10 vials equals one full box.
The minimum is 10 vials, and every additional quantity must be a multiple of 10.
When available, the public English COA is linked to the selected specification. Internal self-inspection COAs remain private in the administration area.
This material is supplied strictly for laboratory and research use and is not intended for human or animal use.
RESEARCH & QUALITY DOCUMENTATION
Content updated · English reference edition
Tesamorelin is a growth-hormone-releasing hormone analogue discussed in endocrine research. It should be identified by its specific molecular identity rather than grouped interchangeably with every peptide associated with growth-hormone signalling. This page provides a catalogue reference and a route into the literature, without claiming that the supplied research material is a finished therapeutic product.
Human randomized trial — defined patient population and formulation
A randomized trial reported by Falutz and colleagues in 2010 studied tesamorelin in HIV-infected participants with abdominal fat accumulation. This is evidence from a defined clinical population and investigational protocol. It should not be generalized into a claim about healthy users, all research applications or the quality of an independently supplied vial. The material used in that trial and the catalogue material must not be assumed to be equivalent.
Reference: Falutz et al., 2010 — randomized tesamorelin study with safety extension ↗
Tesamorelin and ipamorelin are different research compounds, even when both are discussed in growth-hormone-related literature. A combined product also requires component-specific information. Check the exact name, composition and specification before comparing a single-compound listing with a blend.
Review the actual tesamorelin SKU and the corresponding public COA status. Confirm the supplied lot and request missing identity or analytical information when needed. Clinical literature does not replace batch testing, and a COA is not evidence that a laboratory product meets all requirements of a finished medicine.
No. Clinical results concern a specified formulation, protocol and population. They do not establish equivalence or safety of third-party research material.
No. The blend contains multiple components. Review their individual identities and quantities rather than comparing only the total labelled mass.
Request the SKU, intended supplied lot, available analytical documentation and applicable handling information. Confirm that each document refers to the same material.
Sources describe the materials and conditions studied by their authors. They are not endorsements of LYSENTA or certificates for the products on this website.
Related does not mean interchangeable. Check composition and evidence separately.
Browse all research and documentation guides →
For laboratory research only. Not for human or animal use. No clinical dosing, treatment or administration advice is provided.
SAME CATEGORY
